DrugPatentWatch Database Preview
Drugs in Development Information for C1-INH
Email this page to a colleague
See Plans and PricingWhat is the development status for investigational drug C1-INH?
C1-INH is an investigational drug.
There have been 5 clinical trials for C1-INH.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 16th 2016.
The most common disease conditions in clinical trials are Ischemia, Wounds and Injuries, and Reperfusion Injury. The leading clinical trial sponsors are Universitaire Ziekenhuizen Leuven, CSL Behring, and T. van der Poll.
There are fourteen US patents protecting this investigational drug and eighty-eight international patents.
Summary for C1-INH
| US Patents | 14 |
| International Patents | 88 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2016-11-16) |
| Vendors | 0 |
Recent Clinical Trials for C1-INH
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients | CSL Behring | Phase 3 |
| C1-inhibitor in Allergic ASThma Patients | Sanquin | Phase 4 |
| C1-inhibitor in Allergic ASThma Patients | ZonMw: The Netherlands Organisation for Health Research and Development | Phase 4 |
Clinical Trial Summary for C1-INH
Top disease conditions for C1-INH
Top clinical trial sponsors for C1-INH
US Patents for C1-INH
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| C1-INH | Start Trial | Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders | SHIRE VIROPHARMA INCORPORATED (Lexington, MA) | Start Trial |
| C1-INH | Start Trial | Protein biomarkers for immune assessment and prediction of transplant rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) | Start Trial |
| C1-INH | Start Trial | Combination therapy using immunoglobulin and C1-Inhibitor | CSL BEHRING GMBH (Marburg, DE) THE GOVERNMENT OF THE UNITED STATES OF AMERICA (Rockville, MD) | Start Trial |
| C1-INH | Start Trial | Compositions and methods for treating neonatal biliary atresia | Children's Hospital Medical Center (Cincinnati, OH) | Start Trial |
| C1-INH | Start Trial | Process for the purification of C1-inhibitor | The United States of America as represented by the Secretary of the (Washington, DC) | Start Trial |
| C1-INH | Start Trial | Process for preparing a C1-esterase inhibitor concentrate (C1-INH), and concentrate obtained, for therapeutic use | Association pour l'Essor de la Transfusion Sanguine dans (Lille, FR) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for C1-INH
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| C1-INH | Australia | 2015243424 | 2034-04-09 | Start Trial |
| C1-INH | Canada | 2944990 | 2034-04-09 | Start Trial |
| C1-INH | European Patent Office | 3129781 | 2034-04-09 | Start Trial |
| C1-INH | Japan | 2017513009 | 2034-04-09 | Start Trial |
| C1-INH | South Korea | 20160142390 | 2034-04-09 | Start Trial |
| C1-INH | World Intellectual Property Organization (WIPO) | 2015157546 | 2034-04-09 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
